News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY), Ascletis, Inc. to Collaborate on Hepatitis C Drugs for China


4/15/2013 8:46:10 AM

Roche Holding AG (ROG.VX) Mondat said it and Ascletis have entered into a collaboration to develop and commercialize Roche's investigational drug danoprevir in China for the treatment of Hepatitis-C Virus (HCV). - It is estimated that more than 10 million patients in China are chronically infected with HCV. - The majority of these are genotype 1b, which has proven highly responsive to danoprevir. - Roche and Ascletis are joining forces to develop a therapy with the potential to address a serious public health problem and to provide an effective new treatment option for Chinese patients with HCV.

Read at Fox News
Read at Reuters
Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES